Stifel Nicolaus Cuts Geron (NASDAQ:GERN) Price Target to $4.00

Geron (NASDAQ:GERN - Get Free Report) had its target price reduced by analysts at Stifel Nicolaus from $8.00 to $4.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the biopharmaceutical company's stock. Stifel Nicolaus' price objective would indicate a potential upside of 133.92% from the stock's previous close.

Other analysts have also issued research reports about the stock. Needham & Company LLC decreased their target price on shares of Geron from $7.00 to $5.00 and set a "buy" rating on the stock in a report on Thursday. Barclays reissued an "overweight" rating and issued a $4.00 target price (down previously from $9.00) on shares of Geron in a research note on Thursday. HC Wainwright cut shares of Geron from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 26th. Finally, B. Riley cut Geron from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $3.50 to $2.00 in a report on Thursday. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Geron presently has a consensus rating of "Moderate Buy" and an average price target of $5.68.

Geron Stock Performance

Shares of Geron stock traded down $0.05 during trading hours on Thursday, hitting $1.71. 26,505,173 shares of the company's stock traded hands, compared to its average volume of 14,960,415. Geron has a 12-month low of $1.46 and a 12-month high of $5.34. The company has a fifty day simple moving average of $2.93 and a 200-day simple moving average of $3.76. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -5.34 and a beta of 0.53.

Remove Ads

Geron (NASDAQ:GERN - Get Free Report) last released its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.04). The business had revenue of $47.54 million during the quarter, compared to the consensus estimate of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. Equities research analysts anticipate that Geron will post -0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Geron

Several large investors have recently modified their holdings of GERN. SBI Securities Co. Ltd. purchased a new position in Geron in the 4th quarter worth approximately $28,000. Integrated Wealth Concepts LLC bought a new position in Geron in the 4th quarter worth $36,000. GF Fund Management CO. LTD. purchased a new position in shares of Geron during the 4th quarter valued at about $45,000. Fifth Lane Capital LP purchased a new position in Geron during the fourth quarter valued at approximately $53,000. Finally, Readystate Asset Management LP bought a new position in Geron in the 3rd quarter worth $58,000. Hedge funds and other institutional investors own 73.71% of the company's stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.